Companies will combine technologies to generate fully human MASP-2 antibodies

Omeros and Affitech entered an agreement to develop fully human antibodies for Omeros’ MASP-2 program. Financial terms include a technology access fee, a series of milestone payments, and royalties on net sales payable by Omeros.

Omeros holds worldwide exclusive licenses to rights related to MASP-2, the antibodies targeting MASP-2, and the therapeutic applications for those antibodies. Affitech will use its human antibody libraries and AffiScreen™ platform to generate fully human MASP-2 antibodies for Omeros.

MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway. It is linked to multiple potential inflammatory diseases including macular degeneration, rheumatoid arthritis, transplant rejection, and cardiovascular and renal ischemia-reperfusion injury, according to the firms.

Previous articleArunA Obtains Commercialization Rights to Univ. of Georgia’s Human Mesenchymal Stem Cells
Next articleScientists Pinpoint Trio of Factors that Allow HIV to Cross the Blood-Brain Barrier